SCHEMBL5633211

SCHEMBL5633211

CS(=O)(=O)c1cccc(Nc2ncc(C(=O)c3ccccc3)s2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 6/20 0.69
MAPK12 P53778 6/20 0.69
MAPK11 Q15759 6/20 0.69
MAPK14 Q16539 6/20 0.69
KMT2A Q03164 2/20 0.61
NPC1 O15118 5/20 0.59
RAB9A P51151 5/20 0.59
MAPT P10636 2/20 0.59
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
MEN1 O00255 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
PLA2G1B P04054 1/20 0.53
NFKB1 P19838 1/20 0.53
HTT P42858 1/20 0.53
NFKB2 Q00653 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5634234 0.89 MAPK13 (0.69) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL5635603 0.86 MAPK13 (0.56) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL5633319 0.85 MAPK13 (0.55) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL5635269 0.85 MAPK13 (0.70) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL5635164 0.84 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL5634354 0.83 MAPK13 (0.76) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL5634247 0.83 MAPK13 (0.53) MAPK13MAPK12MAPK11MAPK14
SCHEMBL5634466 0.83 NPC1 (0.50) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL5634631 0.81 MAPK13 (0.76) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL5634730 0.81 NPC1 (0.48) MAPK13MAPK12MAPK11MAPK14NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100381429-C Thiazole derivatives HOFFMANN LA ROCHE (CH) 2008-04-16 CN disclosed
US-7253197-B2 Aminothiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
CN-1675188-A Thiazole derivatives HOFFMANN LA ROCHE (CH) 2005-09-28 CN disclosed
EP-1539722-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-15 EP disclosed
US-20040038990-A1 Aminothiazole derivatives HOFFMANN-LA ROCHE INC. 2004-02-26 US disclosed
WO-2004014884-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038990-A1 Aminothiazole derivatives FABP4, GPR119, ABAT MAPK13 3018/4885MAPK12 2608/4885MAPK11 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.